Sunshine capital investments
Collection of 3.2 million Euros through placement on AIM Italy/Alternative Capital Market.
The placement price is equal to Euro 1.00.
The enterprise. Sunshine is an Investment Company that operates in the real estate sector with investments abroad, in the United States, with a predominant focus on the East Coast. In particular, the activity of the Issuer is mainly focused on the direct or indirect acquisition of majority or minority shareholdings in Special Purpose Vehicles under US law (Limited Liability Company or Incorporated) created ad hoc for each initiative concerning real estate to be restructured intended for subsequent resale, distressed assets and income properties with a size for each investment between approximately € 500,000.00 and € 3,000,000.00.
Ultima Ricerca Sunshine capital investments
BREAKING NEWS| In the press release dated August 7, 2025, Litix SpA, an Innovative SME that combines art, technology, tradition, and innovation through three business units offering solutions ranging from the design and production of robotic cells for marble and other materials, to the creation of sculptures and other artistic and design works, to hardware and software development for additive manufacturing and other advanced processes, announced that its subsidiary Aivox Srl will take part, as an industrial partner, in the national research project “More4Neuro – Multi-material 3D Printing for Education in Neurosurgery.” The initiative, led by the University of Milan within the framework of the Partenariati Estesi – HealthTech program, aims to develop next-generation simulators for medical and neurosurgical training, capable of accurately replicating the tactile, mechanical, and structural properties of brain tissues through multimaterial additive manufacturing technologies. Aivox, specialized in computational design, software development, additive manufacturing, and multimaterial 3D printing, will contribute its expertise by taking responsibility for the design of physical models, definition of production processes, and validation of prototypes through iterative development and clinical testing phases. The activities assigned to Aivox have a total value of € 0.68 million, of which € 0.54 million will be covered by public funding. This project marks another step in the strategy outlined in the latest annual report, in which Litix emphasized the importance of diversifying its portfolio with highly innovative projects and strengthening its position in advanced technology markets, based on the belief that technological development and global presence are the key growth drivers in the medium term. Following a transitional year in 2024, which marked the first full year of Aivox’s operations, the participation in More4Neuro confirms the Group’s ability to seize opportunities in high-potential sectors, expanding the intersection between digital manufacturing and specialized education. Considering the information disclosed in the press release, we confirm our recommendation: Target Price € 2.50, BUY Rating and MEDIUM Risk. |
